The Venture Codex

Participated · Equity · May 2026

Athelas develops the Athelas Air platform, an integrated, EHR-like system that combines documentation, billing, revenue-cycle management, and ambient AI tools. The company reports operational outcomes such as a 95% first-pass claim rate, a 50% reduction in denials at Lattimore Physical Therapy’s 35 locations, and clinicians reclaiming six to seven hours per week. Athelas has growing penetration with multi-site networks including Rock Valley Physical Therapy, Cape Cod Rehab, Raleigh Orthopaedic, and telemedicine provider Beam Healthcare. It positions its platform as embedded within provider workflows rather than a standalone point solution and emphasizes analytics-driven denial prevention and payer-rule monitoring. Following the new financing, Athelas is investing in sales leadership and go-to-market execution as it scales. The company recently raised $70 million at a $7 billion valuation.

Participated · Equity · May 2026

Commure operates an AI platform used by over 500 healthcare organizations to automate most revenue cycle work. Its tools are reported to help automate hospital paperwork, reduce costs, and alleviate daily frustrations in patient care. The company recently raised $70 million at a $7 billion valuation in a round led by General Catalyst with participation from Sequoia and Morgan Stanley. The articles do not provide details on revenue, user counts beyond the 500 organizations, or founding year. No specific future product plans or use-of-funds details were described in the provided coverage.

Participated · Equity · Feb 2022

AndHealth operates virtual Centers of Excellence that deliver root-cause, disease-reversal programs, beginning with a Migraine Reversal VCOE and soon launching VCOEs for autoimmune conditions including rheumatoid arthritis, psoriasis, ulcerative colitis and Crohn’s. The company offers its programs as an employer-sponsored benefit, working with self-funded employers and benefits brokers and aligning interests around outcomes and guaranteed patient participation. Leadership includes CEO Matt Scantland and team members from CoverMyMeds, clinical leaders such as Dr. Robert Sheeler, and national virtual practice Medical Director Dr. Robert Darling. AndHealth emphasizes precision behavioral design and system-biology approaches to drive high patient engagement and address comorbid chronic conditions. A University of Maryland study of the Migraine Reversal Program found 60% of severe/chronic participants no longer met ICHD-3 diagnostic criteria after the program, and anecdotal results include an 80% reduction in attacks for a long‑suffering patient. The company highlights a large addressable population—roughly 30 million working-age people affected by these conditions—and positions its model to reduce employer costs, unlock productivity, and advance DEI objectives. AndHealth states it partners with employers, health plans, public entities and individuals to scale its virtual disease-reversal care model.